| scholarly article | Q13442814 |
| P50 | author | Toshihiro Sawabe | Q92376565 |
| P2093 | author name string | Kazuyuki Aihara | |
| Akiyuki Takaya | |||
| Akihiro Kobayashi | |||
| Kosuke Nagasaka | |||
| Toshiki Chiba | |||
| P2860 | cites work | NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 |
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | Q27661554 | ||
| Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection | Q34277031 | ||
| Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure | Q34405182 | ||
| Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association | Q34505315 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut | Q34527664 | ||
| The role of the kidney in heart failure | Q34641418 | ||
| Oxidative stress and endothelial dysfunction in heart failure | Q34667682 | ||
| Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers | Q34823612 | ||
| ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology | Q34830023 | ||
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels | Q35009484 | ||
| Endothelial function: cardiac events | Q36019119 | ||
| Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney | Q36024026 | ||
| Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation | Q37086300 | ||
| Acute heart failure syndromes | Q37392540 | ||
| Venous congestion and endothelial cell activation in acute decompensated heart failure | Q37418264 | ||
| Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medi | Q37721628 | ||
| Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review | Q38058411 | ||
| The relevance of congestion in the cardio-renal syndrome | Q38068778 | ||
| Review of vasodilators in acute decompensated heart failure: the old and the new. | Q38120106 | ||
| The annual global economic burden of heart failure | Q38176481 | ||
| The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital | Q38856943 | ||
| Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers | Q41592382 | ||
| Inhibition of soluble guanylate cyclase by ODQ. | Q42055822 | ||
| Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure | Q42645453 | ||
| Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure | Q43576511 | ||
| Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension | Q46555835 | ||
| Oxidative stress in patients with acute heart failure | Q46660649 | ||
| Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure | Q48260348 | ||
| Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine | Q52437136 | ||
| Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes | Q57628743 | ||
| The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog | Q70334836 | ||
| Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches | Q80472740 | ||
| Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage | Q80492373 | ||
| Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure | Q82693298 | ||
| Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure | Q84553919 | ||
| Why do drugs for acute heart failure fail? | Q84596045 | ||
| Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition | Q88036789 | ||
| Nitrates as a Treatment of Acute Heart Failure | Q88711663 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e00463 | |
| P577 | publication date | 2019-03-04 | |
| P1433 | published in | Pharmacology Research & Perspectives | Q27725410 |
| P1476 | title | A novel soluble guanylate cyclase activator with reduced risk of hypotension by short-acting vasodilation | |
| P478 | volume | 7 |
Search more.